Harmony Biosciences Holdings, Inc.
HRMY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $714,734 | $582,022 | $437,855 | $305,440 |
| % Growth | 22.8% | 32.9% | 43.4% | – |
| Cost of Goods Sold | $156,815 | $121,236 | $83,481 | $55,518 |
| Gross Profit | $557,919 | $460,786 | $354,374 | $249,922 |
| % Margin | 78.1% | 79.2% | 80.9% | 81.8% |
| R&D Expenses | $145,825 | $76,063 | $70,886 | $30,367 |
| G&A Expenses | $110,352 | $95,289 | $84,017 | $63,909 |
| SG&A Expenses | $221,268 | $192,693 | $163,302 | $132,027 |
| Sales & Mktg Exp. | $110,916 | $97,404 | $79,285 | $68,118 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $367,093 | $268,756 | $234,188 | $162,394 |
| Operating Income | $190,826 | $192,030 | $120,186 | $87,528 |
| % Margin | 26.7% | 33% | 27.4% | 28.7% |
| Other Income/Exp. Net | $978 | -$18,634 | -$15,500 | -$50,100 |
| Pre-Tax Income | $191,804 | $173,396 | $104,686 | $37,428 |
| Tax Expense | $46,311 | $44,543 | -$76,782 | $2,831 |
| Net Income | $145,493 | $128,853 | $181,468 | $34,597 |
| % Margin | 20.4% | 22.1% | 41.4% | 11.3% |
| EPS | 2.56 | 2.17 | 3.07 | 0.6 |
| % Growth | 18% | -29.3% | 411.7% | – |
| EPS Diluted | 2.51 | 2.13 | 2.97 | 0.58 |
| Weighted Avg Shares Out | 56,885 | 59,470 | 59,173 | 57,532 |
| Weighted Avg Shares Out Dil | 57,870 | 60,372 | 61,097 | 59,205 |
| Supplemental Information | – | – | – | – |
| Interest Income | $18,542 | $14,730 | $3,126 | $224 |
| Interest Expense | $17,496 | $23,757 | $18,795 | $24,194 |
| Depreciation & Amortization | $24,112 | $24,359 | $23,385 | $18,840 |
| EBITDA | $233,412 | $221,512 | $146,866 | $80,462 |
| % Margin | 32.7% | 38.1% | 33.5% | 26.3% |